TB-500 Loading Phase Dosage Research: What It Means

Research protocols built around TB-500 sometimes describe an initial stretch of more frequent dosing before settling into a lower-frequency schedule — a structure commonly labeled a loading phase followed by a maintenance phase. This reference walks through what TB-500 loading phase dosage research actually establishes, where that terminology comes from, and the reconstitution arithmetic behind converting a loading-phase or maintenance-phase dose into syringe units. It is written for research and educational purposes only and is not medical advice.

What "loading phase" means in a research protocol

A loading phase is a period at the start of a protocol where a compound is administered more often than it will be later on. A maintenance phase is what follows: the same or a similar per-injection dose, given less frequently. The pattern shows up across pharmacology generally — some compounds need a higher initial exposure to reach a steady effect before a lower-frequency schedule can sustain it — but the specific loading-phase timelines circulating for TB-500 come from research-community protocol conventions, not from a single definitive source.

That distinction matters. A loading phase changes how often an injection happens. It does not, by itself, change the concentration of the vial being drawn from, and it does not change the arithmetic used to convert a target dose into syringe units. Those two things — schedule and concentration — are independent variables that happen to appear in the same protocol.

What the published TB-500 research actually establishes

TB-500 is the common research name for a synthetic peptide corresponding to a fragment of Thymosin Beta-4 (Tβ4), a naturally occurring protein. The published research base for Tβ4 and TB-500 is predominantly preclinical — animal models and cell studies — rather than large, controlled human trials. That's consistent with where most popular research peptides currently sit: promising early data, without the human trial base that supports an approved drug label. No published, controlled human trial has established a formal loading-phase dosing schedule specific to TB-500, so any loading-phase timeline discussed here or elsewhere describes a research protocol convention, not a clinically validated schedule. TB-500 has no FDA-approved formulation for any human indication.

Here's how we see it: the reconstitution math is the part of a loading-phase protocol that's actually fixed and verifiable — concentration equals mass divided by water volume, every time, regardless of injection frequency. The loading-versus-maintenance schedule is a variable the available published research doesn't settle. Conflating the two, and treating an unverified schedule with the same certainty as the reconstitution arithmetic, is a common mistake in how TB-500 loading phase dosage research gets discussed.

The reconstitution math behind a loading-phase draw

Concentration is set once, at reconstitution: vial mass divided by the water volume added. A common reference setup for TB-500 scales water to vial size at 1 mL per 10 mg, holding concentration at 10 mg/mL across vial sizes.

Worked example. A 10 mg TB-500 vial reconstituted with 1 mL of bacteriostatic water gives 10 ÷ 1 = 10 mg/mL. That concentration holds for every draw from that vial — a loading-phase injection and a maintenance-phase injection alike — until the vial runs out or a new one is mixed.

Worked example: loading phase vs. maintenance phase

Take a protocol where the per-injection dose is 2.5 mg at every phase, drawn from the 10 mg/mL vial above:

Volume = 2.5 mg ÷ 10 mg/mL = 0.25 mL Units = 0.25 mL × 100 = 25 units

That 25-unit draw is identical whether it happens during a loading week or a maintenance week — the dose and concentration haven't changed, only how often the injection is repeated. The 1 mL vial (100 units total) holds 100 ÷ 25 = 4 injections at that dose.

If a loading phase calls for two injections per week over four weeks, that's 8 injections × 25 units = 200 units total — two full vials, since a single 10 mg vial only supplies 4 injections at 25 units each. A maintenance phase at one injection per week draws from the same 25-unit calculation, and a single vial then lasts 4 weeks instead of 2. The per-injection unit math never changes between the two phases; only how many vials a given phase consumes does.

Why the concentration doesn't reset between phases

The only way the mg-per-unit relationship changes mid-protocol is if a new vial gets reconstituted with a different water volume than the last one. A loading phase spanning several vials needs each one confirmed at the same concentration — or, if a different concentration is intentional, the injection volume recalculated for it. Assuming a new vial matches the old one's concentration without checking is the same error whether it happens between two loading-phase injections or between a loading-phase vial and a maintenance-phase vial.

Common mistakes

• Treating a loading-phase timeline as clinically established. Published TB-500 research doesn't define an official loading-phase schedule. Community protocol conventions are not the same as trial-derived dosing evidence.
• Assuming a higher injection frequency means a different concentration. Frequency and concentration are separate variables. A loading phase changes how often a vial is drawn from, not the mg/mL inside it.
• Confusing mg and mcg mid-protocol. TB-500 research doses are generally expressed in milligrams; 1 mg equals 1000 mcg, and misreading one for the other produces a thousand-fold error.
• Not tracking how many injections remain in a vial. A loading phase draws down a vial faster than a maintenance phase at the same per-injection dose, so running out mid-week means a new vial has to be mixed and its concentration reconfirmed before the next draw.

Use the calculator

For any phase of a protocol, enter the vial size, water volume, and per-injection dose into the peptide dosage calculator to get the exact syringe units, whether the schedule calls for two injections a week or one. For the general TB-500 reconstitution walkthrough and reference vial sizes, see the TB-500 dosage calculator guide, and for choosing a reconstitution ratio that reads cleanly on a syringe, see the TB-500 reconstitution ratio calculator guide. The calculator handles the arithmetic at every phase; this guide explains what the published research does and doesn't establish about the schedule around it.